Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 4119-4126

  Toulany, Mahmoud ^a   Kasten Pisula, Ulla ^b   Brammer, Ingo ^b   Wang, Shaomeng ^c   Chen, Jianyong ^c   Dittmann, Klaus ^a   Baumann, Michael ^d   Dikomey, Ekkehard ^b   Rodemann, H Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ATM PROTEIN; BIBX 1382 BS; DNA DEPENDENT PROTEIN KINASE; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HISTONE H2AX; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SERINE; SMALL INTERFERING RNA; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IRRADIATION; MICRONUCLEUS; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA; CELL LINE, TUMOR; CHROMONES; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELLIPTICINES; ENZYME INHIBITORS; GENES, RAS; HUMANS; MORPHOLINES; MUTATION; ORGANIC CHEMICALS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746088022     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2454     Document Type: Article

References (45)

1. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004;55:433-57.
2. Herbst RS, Bunn PA, Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-24.
3. Dent P, Yacoub A, Contessa J, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003;159:283-300.
4. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-54.
5. Petersen C, Eicheler W, Frommel A, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003;79:469-77.
6. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560-7.
7. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561-6.
8. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
9. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 2003;55:713-23.
10. Baumann M, Krause M, Zips D, et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 2003;79:547-59.
11. Giocanti N, Hennequin C, Rouillard D, Defrance R, Favaudon V. Additive interaction of gefitinib ("Iressa," ZD1839) and ionising radiation in human tumour cells in vitro. Br J Cancer 2004;91:2026-33.
12. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-66.
13. Toulany M, Dittmann K, Baumann M, Rodemann HP. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol 2005;74:117-29.
14. Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann HP. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol. Radiother Oncol 2005;76:143-50.
15. Krause M, Hessel F, Zips D, Hilberg F, Baumann M. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radiother Oncol 2004;72:95-101.
16. Kim IA, Bae SS, Fernandes A, et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005;65:7902-10.
17. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005;76:157-61.
18. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced EGFR nuclear transport is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005;280:31182-9.
19. Krause M, Ostermann G, Petersen C, et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 2005;76:162-7.
20. Krause M, Schutze C, Petersen C, et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 2005;74:109-15.
21. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 2003;107:1030-7.
22. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004;10:6476-86.
23. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.
24. Iliakis G, Wang H, Perrault AR, et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004;104:14-20.
25. Lieber M, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4:712-20.
26. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002;62:6400-4.
27. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550-4.
28. Marangoni E, Foray N, O'Driscoll M, et al. A Ku80 fragment with dominant negative activity imparts a radiosensitive phenotype to CHO-K1 cells. Nucleic Acids Res 2000;28:4778-82.
29. Jin X, Gossett DR, Wang S, et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 2004;91:1808-12.
30. Tang HJ, Jin X, Wang S, et al. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol 2006;100:308-17.
31. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses. Proc Natl Acad Sci U S A 2003;100:5057-62.
32. Kasten-Pisula U, Tastan H, Dikomey E. Huge differences in cellular radiosensitivity are due to only very small variations in double-strand break repair capacity. Int J Radiat Biol 2005;81:409-19.
33. Fenech M. The in vitro micronucleus technique. Mutat Res 2000;455:81-95.
34. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
35. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004;64:2390-6.
36. Wang H, Wang M, Wang H, Bocker W, Iliakis G. Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA-PK in human cells exposed to ionizing radiation and treated with kinase inhibitors. J Cell Physiol 2005;202:492-502.
37. Chan DW, Chen BP, Prithivirajsingh S, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 2002;16:2333-8.
38. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998;273:1568-73.
39. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
40. Momota H, Ichimiya S, Kondo N, et al. Histone H2AX sensitizes glioma cells to genotoxic stimuli by recruiting DNA double-strand break repair proteins. Int J Oncol 2003;23:311-5.
41. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003;5:675-9.
42. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004;279:41189-96.
43. Dragoi AM, Fu X, Ivanov S, et al. DNA- PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J 2005;24:779-89.
44. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-35.
45. Magne N, Fischel JL, Tiffon C, et al. Molecular mechanisms underlying the interaction between ZD1839 ("Iressa") and cisplatin/5-fluorouracil. Br J Cancer 2003;89:585-92.